Transcriptomics and solid tumors: The next frontier in precision cancer medicine.

Transcriptomics, which encompasses assessments of alternative splicing and alternative polyadenylation, identification of fusion transcripts, explorations of noncoding RNAs, transcript annotation, and discovery of novel transcripts, is a valuable tool for understanding cancer mechanisms and identifying biomarkers. Many issues regarding the complexity of the analysis, its reproducibility and variability, and the interpretation of the results still need to be addressed.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Recent advances in high-throughput technologies have enabled large-scale gene expression profiling.
• 2 Importantly, RNA expression profiling of tumor tissue has been successfully used to determine clinically actionable molecular alterations.
• 3 The WINTHER precision medicine clinical trial was the first prospective trial in diverse solid malignancies that assessed both genomics and transcriptomics to match treatments to specific molecular alterations.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: